Hims & Hers Health (NYSE:HIMS) Insider Soleil Boughton Sells 3,461 Shares of Stock

Posted by George Bondi on Oct 16th, 2026

Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) insider Soleil Boughton sold 3,461 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, October 14th. The stock was sold at an average price of $29.06, for a total transaction of $100,576.66. Following the completion of the sale, the insider directly owned 297,348 shares in the company, valued at $8,640,932.88. This trade represents a 1.15% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Soleil Boughton also recently made the following trade(s):

On Wednesday, September 30th, Soleil Boughton sold 3,461 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.17, for a total value of $100,957.37.
On Wednesday, September 16th, Soleil Boughton sold 6,236 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.86, for a total value of $173,734.96.
On Wednesday, September 2nd, Soleil Boughton sold 3,458 shares of Hims & Hers Health stock. The shares were sold at an average price of $28.33, for a total value of $97,965.14.
On Wednesday, August 19th, Soleil Boughton sold 25,111 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.55, for a total transaction of $691,808.05.

Hims & Hers Health Price Performance

NYSE HIMS opened at $29.53 on Friday. The firm’s 50-day simple moving average is $29.32 and its two-hundred day simple moving average is $28.74. Hims & Hers Health, Inc. has a 52 week low of $13.74 and a 52 week high of $63.63. The company has a quick ratio of 0.87, a current ratio of 0.93 and a debt-to-equity ratio of 4.21. The company has a market cap of $6.89 billion, a PE ratio of -46.88 and a beta of 2.44.

Hims & Hers Health (NYSE:HIMS – Get Free Report) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.32). Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The business had revenue of $753.21 million for the quarter, compared to analysts’ expectations of $698.90 million. During the same quarter in the previous year, the company posted $0.17 earnings per share. The business’s quarterly revenue was up 38.2% compared to the same quarter last year. Research analysts predict that Hims & Hers Health, Inc. will post -0.16 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have commented on HIMS shares. Wall Street Zen upgraded Hims & Hers Health from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Truist Financial raised their price objective on shares of Hims & Hers Health from $27.00 to $32.00 and gave the company a “hold” rating in a research report on Monday, August 24th. Morgan Stanley boosted their price objective on shares of Hims & Hers Health from $21.00 to $28.00 and gave the company an “equal weight” rating in a research note on Tuesday, August 11th. Bank of America upped their target price on shares of Hims & Hers Health from $30.00 to $32.00 and gave the stock a “neutral” rating in a report on Tuesday, August 11th. Finally, Canaccord Genuity Group boosted their price target on shares of Hims & Hers Health from $32.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, July 1st. Three research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $32.43.

Check Out Our Latest Stock Report on HIMS

Hedge Funds Weigh In On Hims & Hers Health

A number of institutional investors have recently made changes to their positions in the stock. Bank of America Corp DE increased its stake in Hims & Hers Health by 194.4% in the first quarter. Bank of America Corp DE now owns 4,357,672 shares of the company’s stock valued at $90,465,000 after acquiring an additional 2,877,550 shares during the last quarter. State of Michigan Retirement System increased its position in shares of Hims & Hers Health by 13.7% during the 1st quarter. State of Michigan Retirement System now owns 2,338,600 shares of the company’s stock valued at $48,549,000 after purchasing an additional 280,900 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in shares of Hims & Hers Health during the 2nd quarter valued at about $46,220,000. Bienville Capital Management LLC purchased a new position in shares of Hims & Hers Health during the 2nd quarter valued at about $27,242,000. Finally, Principal Financial Group Inc. raised its holdings in shares of Hims & Hers Health by 97.3% during the 1st quarter. Principal Financial Group Inc. now owns 1,282,266 shares of the company’s stock valued at $26,620,000 after buying an additional 632,282 shares in the last quarter. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health News Roundup

Here are the key news stories impacting Hims & Hers Health this week:

Positive Sentiment: Australian expansion provides a growth catalyst. Hims & Hers launched its “Hers” women’s-health platform in Australia following its acquisition of Eucalyptus, expanding its offerings into weight management, hormonal health and hair regrowth. The move may support international revenue growth and broaden the company’s addressable market. Hims & Hers Expands Australian Women’s Health Platform With Hers
Positive Sentiment: The stock’s rebound may reflect dip-buying. HIMS had suffered a sharp decline in the prior session amid regulatory and litigation concerns, potentially creating room for a technical rebound as investors reassessed the selloff.
Neutral Sentiment: Insider selling was limited and pre-arranged. Director Soleil Boughton sold 3,461 shares for approximately $100,577 under a Rule 10b5-1 trading plan, reducing her position by 1.15%. Because the transaction was scheduled in advance and represents a small portion of her holdings, it offers limited insight into current management sentiment. Soleil Boughton insider transaction
Negative Sentiment: Multiple law firms publicized a securities-fraud class action. The lawsuit follows the FTC’s federal complaint alleging serious business misconduct, including disputed privacy and billing practices. Investors who purchased HIMS securities between August 4, 2025 and July 29, 2026 have until November 2, 2026 to seek lead-plaintiff status. The litigation could raise legal costs, increase reputational pressure and create potential financial liabilities. The numerous October 14–15 announcements largely repeat the same case and should not be interpreted as separate lawsuits. Hims & Hers securities fraud class action notice

About Hims & Hers Health

(Get Free Report)

Hims & Hers Health, Inc is a direct-to-consumer telehealth company that provides access to personalized healthcare through its online platforms, Hims and Hers. The company connects consumers with licensed healthcare professionals for virtual consultations, treatment plans and prescription medications where appropriate.

Its services address a range of common health and wellness needs, including sexual health, hair loss, skincare, mental health, weight management and primary care. Hims & Hers offers branded and generic treatments, over-the-counter products, supplements and personal-care products, with services designed for both men and women.

The company was founded in 2016, launched the Hims brand in 2017 and introduced the Hers brand in 2018.